FABHALTA®
iptacopan

Patient safety card

Important safety information for patients taking FABHALTA®

During treatment, your immune system has a lower ability to fight certain bacterial infections (specifically from encapsulated bacteria).

These infections may cause meningitis, pneumonia, sepsis, or other life-threatening infections. They can cause death if not recognised and treated early.

Keep this card with you at all times during treatment and for 2 weeks after your last dose, and show it to any healthcare professional involved in your care.

Contact your doctor immediately or call 995 and show this card, in case you experience any of the following signs and symptoms of serious infection:

- **Fever**
  - With or without shivers or chills
  - With a headache
  - With a rash
  - With chest pain and cough
  - With breathlessness/fast breathing
  - With high heart rate
- **Headache**
  - With feeling sick (nausea) or vomiting
  - With a stiff neck or stiff back
- **Confusion**
- **Body aches with flu-like symptoms**
- **Clammy skin**
- **Eyes sensitive to light**

Information for healthcare professionals

This patient has been prescribed FABHALTA® (iptacopan) for paroxysmal nocturnal haemoglobinuria (PNH) **with haemolytic anaemia**.

FABHALTA® may increase the patient's susceptibility to serious infections caused by encapsulated bacteria (*Neisseria meningitidis*, *Streptococcus pneumoniae* and *Haemophilus influenzae* Type B). These infections include meningitis, pneumonia and sepsis. Serious infections may rapidly progress and may become life-threatening if not recognised and treated early.

Recognise

Closely monitor patients for early signs and symptoms of serious infection. Immediately evaluate if bacterial infection is suspected.

Treat

Immediate use of antibiotics is vital in cases of suspected meningitis, pneumonia or sepsis.

Inform

Please call the patient's prescribing doctor as soon as possible using the number provided on the last page of this card to receive further information.

For more information about FABHALTA®, please refer to the local Package Insert. Adverse reactions associated with FABHALTA® can be reported to Novartis at https://www.novartis.com/report or by calling Novartis at 6019 6483, or to the Health Sciences Authority at Tel: 6866 1111, or report online at https://www.hsa.gov.sg/adverse-events

In the event of an emergency, please contact 995.

FA-11220373 Aug 2025
This document has been approved by HSA as of 06-AUG-2025

Patient name:

Blood group:

Emergency contact name and number:

Prescribing doctor name and number:

NOVARTIS